Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock

Recruiting N/A Interventional Study
Cardiogenic Shock
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
406 (estimated)
Sponsor
CMC Ambroise Paré · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Cardiogenic shock is a life-threatening condition characterized by inadequate cardiac output, leading to organ hypoperfusion and high mortality. Maintaining mean arterial pressure (MAP) is crucial, but standard targets may be insufficient due to venous congestion. Central venous pressure (CVP) can help assess effective perfusion pressure. This study investigates whether a personalized MAP target a…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Aged ≥18 years * Cardiogenic shock state, according to the consensus definition, * SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C * Consent from the patient or close relative / trusted person or emergency inclusion procedure * Benefiting fro…
Contacts

Armand MEKONTSO DESSAP, MD

+ 33 1 45 17 85 06

armand.dessap@aphp.fr

CONTACT